216 related articles for article (PubMed ID: 36156411)
1. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
2. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
3. Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity.
Shim MK; Yang S; Park J; Yoon JS; Kim J; Moon Y; Shim N; Jo M; Choi Y; Kim K
J Nanobiotechnology; 2022 Oct; 20(1):436. PubMed ID: 36195911
[TBL] [Abstract][Full Text] [Related]
4. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity.
Yang S; Shim MK; Kim WJ; Choi J; Nam GH; Kim J; Kim J; Moon Y; Kim HY; Park J; Park Y; Kim IS; Ryu JH; Kim K
Biomaterials; 2021 May; 272():120791. PubMed ID: 33831739
[TBL] [Abstract][Full Text] [Related]
5. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance.
Kim J; Shim MK; Yang S; Moon Y; Song S; Choi J; Kim J; Kim K
J Control Release; 2021 Feb; 330():920-932. PubMed ID: 33152391
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.
Lee SJ; Jeong YI; Park HK; Kang DH; Oh JS; Lee SG; Lee HC
Int J Nanomedicine; 2015; 10():5489-503. PubMed ID: 26357473
[TBL] [Abstract][Full Text] [Related]
7. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis.
Kim J; Shim MK; Cho YJ; Jeon S; Moon Y; Choi J; Kim J; Lee J; Lee JW; Kim K
Biomaterials; 2021 Dec; 279():121189. PubMed ID: 34695659
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review).
Zhong YJ; Shao LH; Li Y
Int J Oncol; 2013 Feb; 42(2):373-83. PubMed ID: 23291656
[TBL] [Abstract][Full Text] [Related]
9. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy.
Shim MK; Moon Y; Yang S; Kim J; Cho H; Lim S; Yoon HY; Seong JK; Kim K
Biomaterials; 2020 Dec; 261():120347. PubMed ID: 32889501
[TBL] [Abstract][Full Text] [Related]
10. Design and Evaluation of a Carrier-Free Prodrug-Based Palmitic-DEVD-Doxorubicin Conjugate for Targeted Cancer Therapy.
Yang SB; Lee DN; Lee JH; Seo M; Shin DW; Lee S; Lee YH; Park J
Bioconjug Chem; 2023 Feb; 34(2):333-344. PubMed ID: 36735902
[TBL] [Abstract][Full Text] [Related]
11. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin B-Cleavable Cyclopeptidic Chemotherapeutic Prodrugs.
Herceg V; Bouilloux J; Janikowska K; Allémann E; Lange N
Molecules; 2020 Sep; 25(18):. PubMed ID: 32962018
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the antitumor efficacy of peptide-doxorubicin conjugates with different linkers.
Liang Y; Li S; Wang X; Zhang Y; Sun Y; Wang Y; Wang X; He B; Dai W; Zhang H; Wang X; Zhang Q
J Control Release; 2018 Apr; 275():129-141. PubMed ID: 29408580
[TBL] [Abstract][Full Text] [Related]
14. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
[TBL] [Abstract][Full Text] [Related]
15. pH/ROS dual-responsive supramolecular polypeptide prodrug nanomedicine based on host-guest recognition for cancer therapy.
Ding Y; Wang C; Ma Y; Zhu L; Lu B; Wang Y; Wang J; Chen T; Dong CM; Yao Y
Acta Biomater; 2022 Apr; 143():381-391. PubMed ID: 35272024
[TBL] [Abstract][Full Text] [Related]
16. PEGylated Multistimuli-Responsive Dendritic Prodrug-Based Nanoscale System for Enhanced Anticancer Activity.
Duan Z; Cai H; Zhang H; Chen K; Li N; Xu Z; Gong Q; Luo K
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35770-35783. PubMed ID: 30246536
[TBL] [Abstract][Full Text] [Related]
17. Intracellular Activation of a Prostate Specific Antigen-Cleavable Doxorubicin Prodrug: A Key Feature Toward Prodrug-Nanomedicine Design.
Pereira SGT; Hudoklin S; Kreft ME; Kostevsek N; Stuart MCA; Al-Jamal WT
Mol Pharm; 2019 Apr; 16(4):1573-1585. PubMed ID: 30802065
[TBL] [Abstract][Full Text] [Related]
18. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
[No Abstract] [Full Text] [Related]
19. Co-delivery of doxorubicin and curcumin by pH-sensitive prodrug nanoparticle for combination therapy of cancer.
Zhang Y; Yang C; Wang W; Liu J; Liu Q; Huang F; Chu L; Gao H; Li C; Kong D; Liu Q; Liu J
Sci Rep; 2016 Feb; 6():21225. PubMed ID: 26876480
[TBL] [Abstract][Full Text] [Related]
20. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
